Sibirceva, Una

Sibirceva, Una was paid $1.25M by Medicaid between Jan 2018 and Dec 2024, across 17 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.

33Billing provider infoSIBIRCEVA, UNA
BROOKLYN, NY 11235

33aNPI1174777379assigned 11/14/2008

33bProvider typeInternal Medicine Physician

28Total paid$1.25M

24GClaims17,959

24DCodes billed17

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Internal Medicine Physician providers in New York

Rank by total paid#234 of 6,049

Median peer was paid$11K

This provider vs. median110×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,159	$103K
2019	4,001	$363K
2020	3,774	$324K
2021	288	$4K
2022	554	$5K
2023	2,088	$115K
2024incomplete	5,095	$335K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	33%	9,197	7,951	$414K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	19%	1,616	1,616	$233K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	13%	4,057	4,055	$158K
64484		12%	487	486	$151K
62323		9.1%	608	608	$114K
64483		5.6%	495	494	$70K
95910		3.3%	346	345	$41K
95886		2.8%	526	346	$35K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	1.1%	159	155	$13K
93925		1.1%	123	123	$13K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	99	98	$3K
99483	Prolong outpt/office vis	<1%	12	12	$2K

5 more codes

93970		<1%	12	$517.23
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	14	$89.46
G0179	Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care	<1%	12	$56.46
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	76	$41.12
36415	Collection of venous blood by venipuncture	0%	120	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.